Nasri Nahas – CEO, Biopôle
Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this…
Oliver Kuhn, CEO of Selectchemie, has had a diverse career spanning various sectors, starting in the financial industry before transitioning to healthcare. Under his leadership, Selectchemie has sharpened its strong…
Once a traditional Swiss pharmaceutical wholesaler, Unipharma has undergone a profound transformation into a globally oriented, strategy-driven partner for hospitals, pharmaceutical, and biotechnology companies. Under the leadership of CEO Simone…
Five decades since its founding, Helsinn has recently undergone one of the most consequential transformations in its history. Executive Chairman Riccardo Braglia and Group CEO Melanie Rolli reflect on a…
SkyCell is at the forefront of a fundamental shift in pharmaceutical logistics, where AI, real-time monitoring, and sustainability are no longer optional but essential. As pharmaceutical supply chains grow more…
The 2025 Davos World Economic Forum brought together business leaders from multiple industries to debate the challenges and issues facing the world today. The Pharma CEOs in attendance discussed critical…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health.…
The World Health Organisation has highlighted antimicrobial resistance (AMR) as one of the leading global public health and development threats today. AMR occurs when bacteria, viruses, fungi and parasites change…
Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of…
Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational…
Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer,…
See our Cookie Privacy Policy Here
